NEA Management Company, LLC - Q3 2020 holdings

$2.36 Billion is the total value of NEA Management Company, LLC's 54 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 26.1% .

 Value Shares↓ Weighting
SPT SellSPROUT SOCIAL INC$215,449,000
-11.8%
5,596,080
-38.1%
9.12%
-7.1%
ALLK  ALLAKOS INC$184,744,000
+13.3%
2,268,1880.0%7.82%
+19.4%
ADAP  ADAPTIMMUNE THERAPEUTICS PLCadr$136,319,000
-20.3%
17,082,6110.0%5.77%
-16.0%
CRSP SellCRISPR THERAPEUTICS AGnamen akt$132,988,000
-13.4%
1,590,002
-23.9%
5.63%
-8.8%
OYST  OYSTER PT PHARMA INC$125,083,000
-26.9%
5,925,2870.0%5.30%
-23.0%
MRSN SellMERSANA THERAPEUTICS INC$110,966,000
-40.4%
5,959,520
-25.1%
4.70%
-37.3%
RYTM  RHYTHM PHARMACEUTICALS INC$106,450,000
-2.8%
4,912,3060.0%4.51%
+2.3%
BDTX  BLACK DIAMOND THERAPEUTICS INC$104,289,000
-28.3%
3,449,8450.0%4.42%
-24.5%
AKUS  AKOUOS INC$98,306,000
+1.6%
4,298,4880.0%4.16%
+7.0%
NKTX NewNKARTA INC$87,324,0002,904,974
+100.0%
3.70%
IMRA  IMARA INC$81,709,000
-26.4%
4,017,1700.0%3.46%
-22.5%
 TRILLIUM THERAPEUTICS INC$81,514,000
+75.7%
5,736,3630.0%3.45%
+84.9%
MIRM  MIRUM PHARMACEUTICALS INC$80,699,000
-1.0%
4,187,8010.0%3.42%
+4.3%
AUPH  AURINIA PHARMACEUTICALS INC$76,194,000
-9.4%
5,172,6830.0%3.23%
-4.5%
ANNX NewANNEXON INC$75,504,0002,497,661
+100.0%
3.20%
ARDX  ARDELYX INC$71,576,000
-24.1%
13,633,5820.0%3.03%
-20.1%
INZY NewINOZYME PHARMA INC$64,263,0002,444,379
+100.0%
2.72%
CSPR BuyCASPER SLEEP INC$44,766,000
-19.8%
6,226,130
+0.0%
1.90%
-15.6%
GRTX  GALERA THERAPEUTICS INC$39,441,000
+26.6%
4,362,9860.0%1.67%
+33.4%
VRNA BuyVERONA PHARMA PLCads$31,877,000
+458.5%
5,108,563
+318.8%
1.35%
+489.5%
MTCR NewMETACRINE INC$31,273,0003,062,977
+100.0%
1.32%
GLYC  GLYCOMIMETICS INC$27,903,000
-18.4%
9,089,0410.0%1.18%
-14.0%
MEIP  MEI PHARMA INC$26,623,000
-24.5%
8,533,0720.0%1.13%
-20.5%
BE  BLOOM ENERGY CORP$23,960,000
+65.2%
1,333,3330.0%1.02%
+74.1%
TRVI  TREVI THERAPEUTICS INC$23,941,000
-38.8%
5,940,7960.0%1.01%
-35.5%
GNCA BuyGENOCEA BIOSCIENCES INC$23,763,000
+43.0%
10,376,936
+43.6%
1.01%
+50.6%
AVEO  AVEO PHARMACEUTICALS INC$23,481,000
+15.3%
3,952,9580.0%0.99%
+21.5%
GERN NewGERON CORP$23,423,00013,461,538
+100.0%
0.99%
PHAS  PHASEBIO PHARMACEUTICALS INC$23,319,000
-23.7%
6,643,7040.0%0.99%
-19.7%
AFMD  AFFIMED NV$20,769,000
-26.5%
6,126,4880.0%0.88%
-22.7%
CSBR  CHAMPIONS ONCOLOGY INC$15,852,000
-3.2%
1,713,7200.0%0.67%
+1.8%
CTIC  CTI BIOPHARMA CORP$15,352,000
+85.3%
7,140,4500.0%0.65%
+95.2%
IVA NewINVENTIVA SAads$12,312,0001,041,666
+100.0%
0.52%
LQDA  LIQUIDIA TECHNOLOGIES INC$12,231,000
-41.6%
2,486,0620.0%0.52%
-38.5%
TRVN  TREVENA INC$11,397,000
+99.3%
3,811,6910.0%0.48%
+110.0%
OBSV  OBSEVA SA$11,375,000
-57.9%
4,586,5630.0%0.48%
-55.6%
NET SellCLOUDFLARE INC$11,347,000
-92.2%
2,763,583
-31.9%
0.48%
-91.8%
XENE  XENON PHARMACEUTICALS INC$10,983,000
-11.7%
992,1070.0%0.46%
-7.0%
DZSI NewDZS INC$8,960,000956,255
+100.0%
0.38%
SBBP  STRONGBRIDGE BIOPHARMA PLC$8,697,000
-44.4%
4,141,3080.0%0.37%
-41.5%
SYBX  SYNLOGIC INC$8,543,000
-0.5%
4,229,4100.0%0.36%
+4.9%
MRKR  MARKER THERAPEUTICS INC$7,500,000
-27.5%
5,000,0000.0%0.32%
-23.6%
LUMO  LUMOS PHARMA INC$7,278,000
-16.2%
526,6630.0%0.31%
-11.7%
SENS SellSENSEONICS HOLDINGS INC$5,520,000
-11.7%
14,153,201
-11.7%
0.23%
-6.8%
ERYP  ERYTECH PHARMA SAadr$3,750,000
-34.4%
625,0000.0%0.16%
-30.9%
LXRX  LEXICON PHARMACEUTICALS INC$3,430,000
-27.8%
2,382,2860.0%0.14%
-24.1%
MLND  MILLENDO THERAPEUTICS INC$2,880,000
-7.4%
1,766,7790.0%0.12%
-2.4%
TCON  TRACON PHARMACEUTICALS INC$1,793,000
+163.7%
346,7180.0%0.08%
+181.5%
DKNG NewDRAFTKINGS INC$1,406,00023,902
+100.0%
0.06%
RGLS  REGULUS THERAPEUTICS INC$1,055,000
-24.6%
2,052,4550.0%0.04%
-19.6%
AKTX  AKARI THERAPEUTICS PLCadr$787,000
-20.2%
452,1670.0%0.03%
-17.5%
PLTR NewPALANTIR TECHNOLOGIES INCcl a$712,00074,974
+100.0%
0.03%
ALTR NewALTAIR ENGR INC$503,00011,977
+100.0%
0.02%
SNSS SellSUNESIS PHARMACEUTICALS INC$162,000
-52.6%
129,827
-90.0%
0.01%
-50.0%
RIGL ExitRIGEL PHARMACEUTICALS INC$0-3,243,150
-100.0%
-0.24%
DZSI ExitDASAN ZHONE SOLUTIONS INC$0-956,255
-100.0%
-0.34%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-11-06
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GLYCOMIMETICS INC39Q3 20237.6%
AURINIA PHARMACEUTICALS INC37Q3 20235.0%
CHAMPIONS ONCOLOGY INC33Q3 20231.2%
LEXICON PHARMACEUTICALS INC32Q3 20232.0%
ADAPTIMMUNE THERAPEUTICS PLC31Q3 20239.3%
TREVENA INC31Q3 20213.3%
AKARI THERAPEUTICS PLC31Q2 20230.3%
ARDELYX INC29Q3 202111.9%
RIGEL PHARMACEUTICALS INC29Q2 20200.6%
EPIZYME INC28Q1 20209.6%

View NEA Management Company, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-11
13F-HR2023-05-15
13F-HR2023-02-10
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-12

View NEA Management Company, LLC's complete filings history.

Compare quarters

Export NEA Management Company, LLC's holdings